MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why FLGT Stock advanced +0.74% Today — RQD Quant Desk Flash
$21.68 +0.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $21.67
Fulgent Genetics Inc. (FLGT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $596.5M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $21.67 (-0.06%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-10.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for FLGT)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY FLGT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (29% of score)
FRED Regime × Technicals: 47% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (26% of score)
20D Institutional Volume Accumulation (±9.3% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$21.74-8.9% Next Q
42
Q2 (-2Q)Grade E$19.81+1.5% Next Q
39
Q3 (-1Q)Grade E$20.10+7.9% Next Q
37
CurrentGrade E$21.68-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a FLGT Turnaround Squeeze
While FLGT currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.77) and Max Pain ($22.76) forces dealer call-delta covering toward $32.59.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $FLGT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “FLGT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why FLGT Stock advanced +0.74% Today — RQD Quant Desk Flash
Fulgent Genetics Inc. (FLGT) advanced +0.74% to $21.68, trading at 47% of its 52-week range ($13.46 – $31.04). Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 47% of its 52-week range ($13.46 – $31.04) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.3% around $21.68 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 40.6% gross margin and $0 annual free cash flow.
Live FLGT Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring FLGT)
- ✓Walkthrough of FLGT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
FLGT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.73%▲ ASCENDING CHANNEL
2026-10-30O $21.50H $21.77L $20.54C $21.68VOL 201.4K
RES: $23.74SUP: $19.64SMA50: $20.77SMA200: $19.37
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
FLGT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +13.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on FLGT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for FLGT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for FLGT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (FLGT)
Health Care Rank #838 of 1016
⚔️ YDES vs FLGT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (FLGT vs. YDES, LMRI, CSTL, TRUP)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Fulgent Genetics Inc. (FLGT) ranks #838 by composite RQD confidence (34/100, grade E) and #421 by equity capitalization ($596.5M). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while TRUP leads on capital efficiency and profitability with 3.1% ROIC and 16.1% gross margin. TRUP currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with FLGT at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| FLGT
ACTIVE
Fulgent Genetics Inc. | E | 34/100 | — | 40.6% | -6.8% | +0.74% | $596.5M | Benchmark Subject |
| YDES YD Bio Limited | D- | 37/100 | — | 28.1% | -20.0% | -6.53% | $415.8M | /ydes-vs-flgt → |
| LMRI Lumexa Imaging Holdings Inc. | D+ | 58/100 | — | — | — | +0.95% | $1.13B | /lmri-vs-flgt → |
| CSTL Castle Biosciences Inc. | C- | 60/100 | — | 79.4% | -9.3% | +4.99% | $1.18B | /cstl-vs-flgt → |
| TRUP Trupanion Inc. | C | 64/100 | 68.2x | 16.1% | 3.1% | +2.27% | $1.32B | /trup-vs-flgt → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674930In its most recent audited fiscal period (FY2025, filed 2025-12-31), Fulgent Genetics Inc. (FLGT) reported GAAP revenue of $322.7M (+13.8% vs. FY2024 revenue of $283.5M , and +11.6% cumulative change since FY2023) , GAAP net income of -$60.5M, operating cash flow of -$101.6M, and free cash flow of -$124.2M (-545.1% YoY). On the balance sheet, FLGT closed FY2025 with $1.21B in total assets against $0 in total debt (Altman Z-Score: 4.44, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $322.7M | -$60.5M | -$101.6M | -$124.2M | $1.21B | — |
| FY2024 (FY) | 2024-12-31 | $283.5M | -$42.7M | $21.1M | -$19.3M | $1.22B | — |
| FY2023 (FY) | 2023-12-31 | $289.2M | -$167.8M | $27.0M | $27.0M | — | — |
3. FLGT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs FLGT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Fulgent Genetics Inc. (NASDAQ: FLGT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $21.68 (+0.74% 1D, market cap $596.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, FLGT ranks #838 in composite RQD confidence.
How does FLGT compare to YDES and LMRI in the Health Care sector?
Within the Health Care sector (Medical Specialities), FLGT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 40.6%, and ROIC of -6.8%. By comparison, YDES (YD Bio Limited) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.0%, cap $415.8M) and LMRI (Lumexa Imaging Holdings Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.13B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while TRUP leads on capital efficiency (3.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for FLGT?
Per FLGT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674930), Fulgent Genetics Inc. generated $322.7M in revenue (+13.8% YoY), -$60.5M in net income, and -$124.2M in free cash flow against $1.21B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is FLGT trading relative to its 50-day, 200-day, and 52-week technical levels?
FLGT last traded at $21.68 (+0.74% on volume of 210,296 shares), positioning the stock +4.38% above its 50-day simple moving average ($20.77) and +11.93% above its 200-day simple moving average ($19.37). Across its 52-week range of $13.46 to $31.04, FLGT sits at the 46.8% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($19.66 to $23.70).
FLGT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is FLGT stock moving today?
Why FLGT Stock advanced +0.74% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-7% return on capital) under elevated 10-year interest-rate pressure.